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An important challenge in the ﬁeld of Parkinson’s disease (PD) is to develop disease
modifying therapies capable of stalling or even halting disease progression. Coupled to this
challenge is the need to identify disease biomarkers, in order to identify pre-symptomatic
hallmarks of disease and monitor disease progression.The answer to these challenges lies
in the elucidation of the molecular causes underlying PD, for which important leads are dis-
ease genes identiﬁed in studies investigating the underlying genetic causes of PD. LRRK2
and α-syn have been both linked to familial forms of PD as well as associated to sporadic
PD. Another gene, microtubule associated protein tau (MAPT), has been genetically linked
to a dominant form of frontotemporal dementia and parkinsonism linked to chromosome 17
(FTDP-17) and genome-wide association studies report a strong association betweenMAPT
and sporadic PD. Interestingly, LRRK2, α-syn, and tau are all phosphorylated proteins, and
their phosphorylation patterns are linked to disease. In this review, we provide an overview
of the evidence linking LRRK2, α-syn, and tau phosphorylation to PD pathology and
focus on studies which have identiﬁed phosphatases responsible for dephosphorylation
of pathology-related phosphorylations. We also discuss how the LRRK2, α-syn, and tau
phosphatases may point to separate or cross-talking pathological pathways in PD. Finally,
we will discuss how the study of phosphatases of dominant Parkinsonism proteins opens
perspectives for targeting pathological phosphorylation events.
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INTRODUCTION
Parkinson’s disease (PD) is an incurable disease of aging character-
ized by the progressive death of dopaminergic cells in themidbrain
as well as by α-synuclein-rich intracytoplasmic depositions called
Lewy bodies (LBs). Treatments which alleviate disease symptoms
have been available for several decades; however, these do not halt
disease progression. The development of disease-modifying ther-
apies to replace the symptomatic treatments is therefore a major
priority in the biomedical research ﬁeld. Genetic studies of fami-
lies with a history of PD (genetic linkage studies) as well as of PD
patient groups compared to matched groups of healthy individu-
als (genetic association studies) have identiﬁed genes and genomic
variants which contribute to the development of PD (Gasser, 2009;
Nalls et al., 2011). These studies have revealed at least 20 PD genes,
many of which are currently the subject of studies aiming to under-
stand their biology and disease mechanisms. For instance, several
PD genes, such as parkin, DJ-1, Pten induced kinase 1 (PINK1), or
ATP13A2, contribute to early onset autosomal recessive forms of
Parkinsonism. Other genes are linked to Parkinsonism in an auto-
somal dominant fashion and are responsible for early onset forms
of PD (α-synuclein duplications or triplications, some families
with mutated α-synuclein) as well as the more common late onset
forms of Parkinsonism (α-synucleinmutants, tau, LRRK2,VPS35,
or EIF4G1; Houlden and Singleton, 2012). In this review, we focus
on the dominant proteins α-synuclein, tau, and LRRK2 in light
of the importance of their phosphorylation for their biological
functioning.
Mutations in α-synuclein (SNCA, PARK1/4) and mutations in
leucine-rich repeat kinase type 2 (LRRK2, PARK8) are linked to
autosomal-dominant forms of PD (Gasser, 2009). Also, although
protein deposition of microtubule associated protein tau (MAPT)
is a feature of Alzheimer’s disease (AD), MAPT gene mutations
cause frontotemporal dementia (FTD) with Parkinsonism. Inter-
estingly, these three dominant genes in Parkinsonism (MAPT,
SNCA, and LRRK2) have also been identiﬁed as risk factors
for sporadic PD in genome-wide association studies (GWAS;
Taymans and Cookson, 2010; Sharma et al., 2012). The dominant
mode of disease transmission through these genes also suggests
a gain of toxic function mechanism pointing to an inhibition of
toxic function as potential therapeutic strategies.
LRRK2, α-syn, and tau are all phosphorylated proteins, and
their phosphorylation patterns are linked to disease (Lobbestael
et al., 2012; Tenreiro et al., 2014). Early work showed that hyper-
phosphorylation of tau is correlated to pathology of tauopathies
and phosphorylation of α-syn at serine129 is correlated to synucle-
inopathies (for reviews, see references Martin et al., 2011; Tenreiro
et al., 2014); therefore much work has focused on identifying and
characterizing kinases of these proteins (for reviews, see references
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Vancraenenbroeck et al., 2011; Martin et al., 2013b; Tenreiro et al.,
2014). The characterization of LRRK2 phosphorylation and the
link to disease is still underway although some evidence suggests
that a site-dependent mixed phosphorylation state is indicative of
disease. Tau and synuclein kinases have been considered as poten-
tial therapeutic targets for synucleinopathies and tauopathies and
several compounds have been developed for these kinases and
tested in preclinical models (for reviews on these topics, see ref-
erences Vancraenenbroeck et al., 2011; Kramer et al., 2012; Tell
and Hilgeroth, 2013). In this review, we will discuss the second
main component in the regulation of protein phosphorylation
of LRRK2, α-syn, and tau, namely phosphatases. We will brieﬂy
introduce the three proteins and discuss what is known about their
dephosphorylation and which phosphatases and phosphatase reg-
ulators are involved.We will also discuss the relationships between
the three proteins with regards to their cognate phosphatases
and discuss targeting of phosphatase holoenzymes of LRRK2,
α-syn, and tau as a potential phosphomodulatory therapeutic
approach.
ALPHA-SYNUCLEIN
The involvement of α-syn in PD was initially identiﬁed
through genetic linkage studies in a small number of families
(Polymeropoulos et al., 1997), including mutations as well as
gene duplications (Chartier-Harlin et al., 2004) and triplications
(Singleton et al., 2003). Recently, strong association was shown
between α-syn and sporadic PD in GWAS (Satake et al., 2009;
Simon-Sanchez et al., 2009). Also, α-syn is a major component of
LBs (Spillantini et al., 1997). These arguments illustrate that α-syn
is a central player in the pathogenesis of PD.
Studies investigating the phosphorylation of α-syn in diseased
and aged brains have shown that α-syn can be phosphorylated at
serines (S87, S129) as well as at several tyrosines including Y125,
Y133, and Y136 (Figure 1). The pY125 modiﬁcation has been
reported to be inversely correlated with PD-related pathology.
Indeed, pY125 appears to protect brains against α-syn mediated
toxicity, as this modiﬁcation is reduced in aged human brain tis-
sue and absent in brain tissue affected by Lewy body dementia
(Chen and Feany, 2005; Chen et al., 2009). The pS129 mod-
iﬁcation on the other hand is most often correlated with PD
pathology. This notion is primarily supported by the ﬁnding that
the majority of α-syn in LBs in postmortem PD brains is phos-
phorylated at S129 (pS129; Fujiwara et al., 2002; Hasegawa et al.,
2002; Anderson et al., 2006). The S129 phosphorylation of α-syn
in aggregates has also been observed in animal models of PD
(Kahle et al., 2000; Neumann et al., 2002; Takahashi et al., 2003).
Mechanistic studies have shown that aggregated forms of α-syn
are more prone to phosphorylation and that pS129 phosphory-
lated aggregates accumulate as the disease progresses (Waxman
and Giasson, 2008; Mbefo et al., 2010; Paleologou et al., 2010;
Waxman and Giasson, 2011), suggesting that the degree of α-syn
pS129 phosphorylation is an indicator of disease progression.
The link between S129 phosphorylation and PD pathology has
fueled an interest in modulating α-syn phosphorylation at S129
as a potential therapy for PD (Vancraenenbroeck et al., 2011).
Multiple kinases have been identiﬁed which phosphorylate α-
syn at S129, with most evidence pointing to polo-like kinase 2
(PLK2) as the primary phosphorylated of α-syn S129 [for an
extended up to date review of α-syn phosphorylation, please
refer to Tenreiro et al. (2014)]. A straightforward therapeutic
approach based on reducing α-syn phospho-S129 would be to
inhibit PLK2 kinase activity; however some contradictory ﬁnd-
ings should be taken into account. For instance, overexpression
of PLK2 in rat brain using adeno-associated viral vectors can
suppress α-syn toxicity by promoting autophagy-mediated degra-
dation of phospho-S129 α-syn (Oueslati et al., 2013). Therefore,
therapies based on modulating α-syn phospho-S129 appears to
require an optimal phosphorylation level rather than a complete
dephosphorylation.
PHOSPHATASES OF α-SYN
Few studies have sought to identify phosphatases of α-syn
(Braithwaite et al., 2012); however, concurring data point to PP2A
as amajor phosphatase of the S129 site. For instance, PP2A enzyme
but not PP1 is shown to dephosphorylate α-syn-pS129 in vitro
(Lee et al., 2011), and treatment of cells with the PP2A inhibitor
okadaic acid (OA) but not the PP1 inhibitor tautomycin leads to an
increased level of α-syn-pS129. Further characterization showed
that α-syn-pS129 was increased upon knockdown of the PP2A
catalytic subunit and when PP2A enzyme is methylated.
FIGURE 1 | Schematic of α-synuclein and its phosphorylation sites.
α-syn is a small protein of 140 amino acids in length. It is subdivided
into three domains, an N-terminal alpha-helical domain, a central NAC
domain (standing for non-Abeta-component) and an acidic C-terminal
domain. The S129 site is hyperphosphorylated in disease and is regulated
by a phosphatase of the heterotrimeric PP2A class. Please refer to
Table 1 for an overview of studies on phosphatases regulating α-syn
phosphorylation.
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It is important to note that the phosphatases of the PP2A class
function in complexes called holoenzymes, which are composed of
regulatory and catalytic phosphatase subunits. In the case of PP2A
phosphatases, these are composed of a catalytic subunit (PPP2CA
or PPP2CB) together with a scaffold subunit (Aα or Aβ) and a
regulatory subunit (of which there are four families, B, B′, B′′, and
B′′′, each with 2–5 different members). The precise heterotrimeric
composition of the holoenzyme guides PP2A to speciﬁc substrate
sites. Accordingly, the testing of four different holoenzyme com-
positions shows that holoenzymes with regulatory subunits of the
B family aremore efﬁcient at dephosphorylatingα-syn-pS129 than
those of the B′ and B′′ families. Interestingly, α-syn may function
in a feedback loop with PP2A, with studies reporting that α-syn
has the ability to activate PP2A activity (Peng et al., 2005) and that
phospho-S129 α-syn is less efﬁcient at activating PP2A (Lou et al.,
2010).
PP2A enzymes have the particularity that their enzymatic activ-
ity is positively regulated by itsmethylationwhich is itself regulated
via the opposing activities of a PP2A-speciﬁc methyltransferase
and aPP2A-speciﬁcmethylesterase (PME).Accordingly, treatment
of mice with the PME inhibitor eicosanoyl-5-hydroxytryptamide
(EHT) increases PP2A methylation as well as decreased α-syn-
pS129 levels in brain and a concurrent reduction in synuclein
pathology (Lee et al., 2011). Related to this, the diabetes drug
metformin was shown to reduce α-syn phosphorylation at S129
through activation of PP2A and inhibition of mammalian target
of rapamycin (mTOR; Perez-Revuelta et al., 2014). These studies
conﬁrm a primordial role of PP2A in the phosphoregulation of
α-syn at S129 and also provide a proof-of-principle that phos-
phorylation levels of α-syn can be modulated by targeting its
phosphatases. Thus far, no phosphatases have been described for
the tyrosine phosphorylation sites of α-syn. An overview of α-syn
phosphatases is given in Table 1.
LRRK2
LRRK2 is a complex protein of 2527 amino acids containing sev-
eral predicted functional domains (Figure 2). Several arguments
underline the importance of LRRK2 for PD. First, LRRK2 is one of
themost prevalent causes of monogenic PD. Furthermore, LRRK2
mutations are present in apparently sporadic cases of PD, with
prevalences of 2% to up to 40% in certain population groups and
LRRK2 was recently genetically associated to PD in several inde-
pendent GWAS (Satake et al., 2009; Simon-Sanchez et al., 2009).
Finally, PD patients carrying the LRRK2mutations show a clinical
and neuropathological proﬁle which is virtually indistinguishable
to sporadic PD (Healy et al., 2008), indicating that LRRK2 may
contribute to a PD disease pathway common to both familial and
sporadic PD.
LRRK2 is a highly phosphorylated protein and phosphosite
mapping studies have distinguished two notable clusters of phos-
phorylation sites, one in or near the Ras of complex proteins
(ROC) domain (Greggio et al., 2009; Kamikawaji et al., 2009) and
another in the interdomain region between the ankyrin repeat
(ANK) and leucine rich repeat (LRR) domains (see Figure 2; West
et al., 2007; Gloeckner et al., 2010; Nichols et al., 2010; see reference
Lobbestael et al., 2012 for a detailed overview of studies reporting
LRRK2 phosphorylation sites).
The physiological and pathological relevance of LRRK2 phos-
phorylation has only just begun to be described. For instance,
phosphosites of the ANK-LRR interdomain region, including the
S910/S935/S955/S973 sites, are sites phosphorylated by upstream
kinases. These sites are detectable in basal conditions in multi-
ple cellular and tissular systems, including for endogenous LRRK2
in Swiss 3T3 or NIH3T3 cells (Nichols et al., 2010; Lobbestael
et al., 2013), mouse primary neurons (Lobbestael et al., 2013),
mouse brain, kidney, and lung (Deng et al., 2011; Choi et al.,
2012; Zhang et al., 2012; Delbroek et al., 2013), mouse embryonic
ﬁbroblasts (Dzamko et al., 2012), mouse bone marrow derived
macrophages (Dzamko et al., 2012) and human peripheral blood
mononuclear cells (Dzamko et al., 2013). The S910 and S935 sites
mediate an interactionof LRRK2with 14-3-3proteins and regulate
LRRK2 cellular localization (Nichols et al., 2010). The search for
the kinases responsible for phosphorylating LRRK2 at this cluster
is still ongoing. Studies in vitro and in COS-7 cells have suggested
a role for protein kinase A as an upstream kinase of the S910–S935
sites (Muda et al., 2014), however, these ﬁndings are not conﬁrmed
in other cell types such as HEK293T cells (Reynolds et al., 2014),
suggesting cell-speciﬁc mechanisms of phosphorylation. This is
Table 1 | Overview of studies reporting phosphatases regulating α-syn phosphorylation.
Site Identified phosphatase Comments, references
S129 PP2A In vitro incubation with PP2A [catalytic subunit Cα (PPP2CA), regulatory subunit Bα (PPP2R2A)] dephosphorylates
α-syn S129 better than with B′α (PPP2R5A), B′γ (PPP2R5C), or B′ ′ (PPP2R3A). Knockdown of PPP2CA or PPP2R2A
increases α-syn S129 phosphorylation (Lee et al., 2011).
PPP2R1A siRNA mediated knockdown of PPP2R1A (Protein phosphatase 2 (formerly 2A), regulatory subunit A,
alpha isoform) reported to decrease α-syn S129 phosphorylation levels in neuroblastoma derived cells
(Henderson-Smith et al., 2013).
PTPRA siRNA mediated knockdown of PPP3R1 (Protein tyrosine phosphatase, receptor type, A) reported to decrease α-syn
S129 phosphorylation levels in neuroblastoma derived cells (Henderson-Smith et al., 2013).
PPP3R1 siRNA mediated knockdown of PPP3R1 (Protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform)
found to increase α-syn S129 phosphorylation levels in neuroblastoma derived cells (Henderson-Smith et al., 2013).
See text for references to reviews discussing α-syn kinases.
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FIGURE 2 | Schematic of LRRK2 domain structure and currently
identified LRRK2 phosphatases. Phosphorylation sites are indicated
above the LRRK2 schematic, for those sites conﬁrmed independently by
at least two different groups. Sites represented in blue indicate cellular
transphosphorylation sites, in orange in vitro autophosphorylation sites
and in green autophosphorylation sites conﬁrmed in cells. Disease
mutants are indicated below the schematic in black, mutations in italics
are risk factor mutations. Arrows (for S910/S935/S955/S973/S1292)
indicate the most common regulation of phosphorylation (up or down)
observed across most disease mutants. Different sites are likely
regulated in different ways, including through PP1 and a yet to be
deﬁned phosphatase sensitive to okadaic acid (OA). Please refer to
Table 2 comparing the regulation of phosphorylation at S935 compared
to S1292.
further supported by the work of Dzamko et al. (2012) who show
that inhibitor of kappa B kinases (IKKs) phosphorylate LRRK2
in bone marrow-derived macrophages upon activation of toll-
like receptor signaling which is speciﬁc to immune cells. The
phosphorylation pattern of LRRK2 is completely different from
that of its closest homolog LRRK1 which does not contribute
to PD, suggesting that phosphorylation regulation of LRRK2
is a potential mechanism distinguishing LRRK2 from LRRK1
functionally.
Phosphorylation levels of the ANK-LRRK interdomain phos-
phosites are reduced for several pathogenic mutants such as
R1441C/G, Y1699C, I2020T (Nichols et al., 2010; Li et al., 2011;
Lobbestael et al., 2013). This observation suggests that the reduc-
tion in LRRK2 phosphorylation levels may be involved in the
pathogenic mechanism of LRRK2 PD. A corollary of that con-
clusion is that reduced LRRK2 phosphorylation may be used as
a biomarker, however, there are some caveats. For instance, the
most prevalent LRRK2 variant in patients, G2019S, does not dis-
play reduced phosphorylation levels and a recent study reported
no differences in LRRK2 S935 phosphorylation in PBMCs of PD
patients compared to matched healthy individuals (Dzamko et al.,
2013). Nevertheless, the striking phosphorylation reduction at the
ANK-LRR sites seen in all other conﬁrmed LRRK2 pathogenic
mutants warrants further evaluation as a disease or diagnostic
biomarker.
The other major group of phosphorylation sites for LRRK2
is comprised of autophosphorylation sites. These are sites which
were initially identiﬁed on LRRK2 protein after in vitro incuba-
tion with ATP to allow the protein to autophosphorylate itself
(Greggio et al., 2009; Kamikawaji et al., 2009; Gloeckner et al.,
2010). The majority of these sites cluster in the ROC domain
and studies with phospho-mimicking mutants show that at least
someof thesemodiﬁcations (T1491D,T1503D) alter LRRK2GTP-
binding properties (Kamikawaji et al., 2009; Webber et al., 2011).
The precise physiological relevance of autophosphorylation sites
is unknown since the majority of these sites are undetectable
in cells, even on overexpressed protein. The notable exceptions
are the T1410 site located in the ROC domain identiﬁed in
overexpressed LRRK2 in HEK293T cells (Pungaliya et al., 2010),
the S1058 (Reyniers et al., 2014), and the S1292 site (Gloeckner
et al., 2010; Pungaliya et al., 2010; Sheng et al., 2012), located in
the 3rd and 13th of the 14 leucine-rich repeats of the leucine-
rich repeat domain, respectively, just outside the ROC domain
(Vancraenenbroeck et al., 2012). These reports suggest that at least
some autophosphorylation events are occurring in cells. Speciﬁ-
cally, the S1292 site has been characterized in more detail and
displays a number of interesting features. The S1292 site is one
of the few autophosphorylation sites located outside ROC. The
site is phosphorylated at detectable levels in basal conditions in
LRRK2 overexpressed in cell lines or in transgenic mice (Sheng
et al., 2012) as well as on endogenous LRRK2 in lymphocytes
(Reynolds et al., 2014). In contrast to what is described for the
ANK-LRR interdomain sites, the S1292 levels are increased in
cells for the majority of pathogenic mutants and decreased in
LRRK2 kinase-dead variants (Sheng et al., 2012; Reynolds et al.,
2014). Increased phosphorylation levels at S1292 may there-
fore be indicative of LRRK2’s pathogenic state; however, this
remains to be tested in PD patients. Because the kinase activat-
ing mutant G2019S shows increased phospho-S1292 and kinase
dead mutants show reduced phospho-S1292, it may be suggested
that phospho-S1292 levels are indicative of LRRK2 kinase activ-
ity in cells, however, some discrepancies appear. For instance,
other mutants, such as N1437H, R1441C, or R1441G which are
signiﬁcantly less active in their kinase activity than G2019S never-
theless display similar phospho-S1292 levels relative to theG2019S
(Sheng et al., 2012; Reynolds et al., 2014). Two other pathogenic
mutants, Y1699C and I2020T, which display kinase activity sim-
ilar to WT or slightly increased, show varying phospho-S1292
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levels depending on the system tested. Indeed, the Y1699Cmutant
displays increased phospho-S1292 levels in stable overexpression
HEK293T cells (Reynolds et al., 2014) and unchanged phospho-
S1292 levels in transfected HEK293T cells (Sheng et al., 2012),
while the inverse is true for the I2020T mutant. Further work
will be required to elucidate the precise regulation of phospho-
S1292 levels in LRRK2. It also remains to be shown whether
the conclusions here for S1292 (an autophosphorylation site
which occurs in cells) also hold true for other autophosphory-
lation sites or whether this is a new ‘class’ of sites (besides the
ROC autophosphorylation cluster and theANK-LRR interdomain
cluster).
Of importance for the development of LRRK2 kinase inhibitors
is that the majority of these sites is downregulated by kinase
inhibitors and may therefore be used to assess inhibitor activ-
ity. For instance, the phosphorylation of autophosphorylation
sites such as S1491 is inhibited by LRRK2 kinase inhibitors in
vitro (Doggett et al., 2012). Also, cellular treatment with kinase
inhibitors leads to a dephosphorylation of the ANK-LRR interdo-
main sites S910/S935/S955/S973 (Dzamko et al., 2010; Deng et al.,
2011; Doggett et al., 2012) as well as the S1292 autophosphory-
lation site (Sheng et al., 2012; Reynolds et al., 2014). Intriguingly,
although the ANK-LRR interdomain phosphorylations are not
autophosphorylation sites, the observed dephosphorylation of
LRRK2 by kinase inhibitors can be attributed to the activity of
the inhibitors on LRRK2 itself.
In sum, the emerging picture of LRRK2 phosphorylation is
that LRRK2 is a highly phosphorylated protein where at least
two, perhaps three, classes of phosphorylation sites can be dis-
cerned (see Figure 2). A ﬁrst class of phosphosites in LRRK2
is the in vitro autophosphorylation site class. These sites appear
after in vitro autophosphorylation by puriﬁed LRRK2; however,
their presence in cells is not conﬁrmed. While these sites offer
opportunities to develop assays of LRRK2 kinase activity, their
physiological relevance is unclear. Further work will be required
to determine whether these sites occur in physiological systems
under speciﬁc conditions of activation, or whether the appear-
ance of these phosphorylations is an in vitro phenomenon. A
second class of LRRK2 phosphorylation sites may be termed ‘cel-
lular’ phosphorylation sites, including those sites of the ANK-LRR
interdomain region introduced above, exempliﬁed by the S935
site. Finally, the third and most recent class of LRRK2 phospho-
rylation sites is the class of cellular autophosphorylation sites,
exempliﬁed by the S1292 site, which are detected in cells and
which also increase after in vitro autophosphorylation. The cel-
lular sites (S935) and cellular autophosphorylation sites (S1292)
are the most physiologically relevant and the comparison of both
sites (summarized in Table 2) suggests that these may be useful
indicators of LRRK2 activity or pathology. With a few exceptions,
pathogenic mutants of LRRK2 display decreased phospho-S935
levels and increased phospho-S1292 levels. It remains to be con-
ﬁrmed whether these changes can be used as diagnostic or disease
biomarkers, either individually or together. Interestingly, cellular
treatment with kinase inhibitors leads to a reduction of both S935
and S1292. Therefore, both sites are also useful as pharmacody-
namic marker to assess activity of kinase inhibitors in cellular and
animal models.
Table 2 | Comparison of the two different LRRK2 phosphorylation sites
pS935 and pS1292.
Parameter pS935 pS1292
Present in cells YES YES
Change after in vitro
autophosphorylation
NO CHANGE INCREASE
Change after cellular
kinase inhibition
DECREASE DECREASE
N1437H vs.WT / HIGHER
R1441C/G vs.WT LOWER HIGHER
Y1699C vs.WT LOWER SIMILAR
G2019S vs.WT NO CHANGE HIGHER
I2020T vs.WT LOWER HIGHER
G2385R vs.WT LOWER LOWER
Regulation IKK, PP1, +tbd AutoP, +tbd
Physiological role 14-3-3 binding,
subcellular localization
Putative role in neurite
length regulation
Indicated is the regulation of phosphorylation levels at these sites by
autophosphorylation, cellular kinase inhibition, or disease mutants. AutoP,
autophosphorylation; tbd, to be discovered.
PHOSPHATASES OF LRRK2
We recently reported that protein phosphatase 1 (PP1) is a
main phosphatase of the LRRK2 ANK-LRR interdomain sites
(Lobbestael et al., 2013). The study ﬁrst shows that of a panel of
recombinant serine/threonine phosphatases, only protein phos-
phatase 1 can efﬁciently dephosphorylate LRRK2 in vitro. In vitro
dephosphorylation was demonstrated on puriﬁed LRRK2 pro-
tein which was previously metabolically labeled by radioactive
phosphates, showing that PP1 is responsible for dephospho-
rylation at the majority of LRRK2’s phosphosites, a ﬁnding
conﬁrmed for 4 sites with phospho-speciﬁc antibodies, i.e., S910,
S935, S955, and S973. Upon pharmacological inhibition of
cells with either PP1 or PP2A phosphatase inhibitors, it was
observed that PP1 but not PP2A inhibition could reverse LRRK2
dephosphorylation.
Interestingly, the effects of PP1 in LRRK2 phosphorylation
could be conﬁrmed in multiple cell types including HEK293T,
SH-SY5Y neuroblastoma cells, mouse primary cortical neurons,
U2OSosteosarcomacells,NIH3T3mouseﬁbroblast cells andA549
human lung cancer cells. This shows that PP1 is active as a LRRK2
phosphatase independent of the cell type tested, and it may be
predicted that PP1 can dephosphorylate LRRK2 throughout the
body.
Similar to PP2A phosphatases, PP1 class phosphatases are
holoenzymes which are composed of one catalytic subunit,
responsible for catalyzing the actual dephosphorylation event, and
one regulatory subunit, responsible for directing the holoenzyme
to its speciﬁc substrates. There are more than 150 PP1 regula-
tory subunits reported, allowing several 100 possible holoenzyme
compositions (Bollen et al., 2010). This mode of functioning is
necessary given that only three PP1 catalytic subunits are expressed
in mammalian cells (PP1α, PP1β, and PP1γ; HGNC codes
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PPP1CA, PPP1CB, and PPP1CC) which on their own are insuf-
ﬁciently diverse to account for the speciﬁcity in the huge volume
of phosphatase activity mediated by PP1. Indeed, PP1 together
with PP2A (which is represented by only two catalytic subunits,
PPP2CA and PPP2CB, see below) account for more than 90% of
the protein phosphatase activity in eukaryotes (Moorhead et al.,
2007; Virshup and Shenolikar, 2009). This is in stark contrast to
the diversity for instance of kinases, of which there are ∼400 ser-
ine/threonine kinases (Manning et al., 2002). Therefore, a key issue
is to identify the composition of the PP1 holoenzyme by identi-
fying the LRRK2-speciﬁc PP1 regulatory subunit which associates
with the PP1 catalytic subunit.
There is little data available on the phosphatases involved in
the regulation of LRRK2 phosphosites outside of the ANK-LRR
interdomain region, however, initial evidence suggests that other
phosphatases are at play. Work done at the S1292 site shows that
inhibitor induced dephosphorylation of LRRK2 at S1292 is insen-
sitive to the phosphatase inhibitors calyculin A (mixed PP1 and
PP2A inhibitor) and OA (selective PP2A inhibitor; Reynolds et al.,
2014), in contrast to what is observed at the S935 site where
inhibitor induced dephosphorylation is inhibited by calyculin A
(Lobbestael et al., 2013). However, the low basal S1292 phosphory-
lation levels of theR1441Gmutant is upregulated by both calyculin
A and OA treatment (Reynolds et al., 2014), while the S935 phos-
phorylation levels of the same mutant is only upregulated by
calyculin A (Lobbestael et al., 2013). These ﬁndings suggest the
hypothesis that PP2A, rather than PP1, is the phosphatase system
regulating R1441G LRRK2 at S1292.
TAU
It may seem surprising to discuss Tau in relation to PD pathogene-
sis, as this protein has a relatively long history as a protein involved
in neurodegenerative dementias; however, accumulating evidence
puts this protein to the forefront in PD with a number of reports
pointing to speciﬁc properties of Tau in PD distinguishing it from
Tau in other neurodegenerative disorders. Tau is a microtubule
associating protein which is involved in several neurodegenera-
tive diseases including AD, progressive supranuclear palsy (PSP),
corticobasal degeneration (CBD), and some cases of frontotem-
poral lobar dementia (FTLD). Although tau is mostly associated
to dementias, the tau gene has also been identiﬁed as a risk fac-
tor for PD via genome wide association studies (GWAS; Sharma
et al., 2012). The genetic association of MAPT locus variants with
PD is a striking ﬁnding, and is in stark contrast with the fact that
no genetic associations of the MAPT locus are observed in AD
(Lambert et al., 2013), showing that tau contributes to both AD
and PD but via separate mechanisms.
Tau can occur in six different splice isoforms ranging in size
from 352 to 441 amino acids and at least 45 potential tau phos-
phorylation sites have been reported, including serine, threonine
and tyrosine phosphorylation sites [see ﬁgure schematic repre-
sentation of tau protein and the localization of phosphorylation
sites, Figure 3; for reviews of tau phosphorylation, please refer to
Martin et al. (2013a,b) and Tenreiro et al. (2014)]. Several kinases
have been reported to phosphorylate tau. These include pro-
line directed kinases [glycogen synthase kinase 3 (GSK3), cyclin
dependent kinase 5 (CDK5), and 5′ adenosine monophosphate-
activated protein kinase (AMPK)], non-proline directed kinases
[casein kinase 1 (CK1), microtubule afﬁnity regulating kinases
(MARKs), death associated protein kinase 1 (DAPK1), cyclic
AMP-dependent protein kinase A (PKA) and dual speciﬁcity
tyrosine-phosphorylation regulated kinase 1A (DYRK-1A)] aswell
tyrosine kinases including Fyn, Abl, and Syk. The inhibition of
tau phosphorylation has been proposed as a therapeutic strategy
in tauopathies including early phase clinical testing of GSK-3β
inhibition (Del Ser et al., 2013).
Tau phosphorylation is important for tau function/dysfunction
as hyperphosphorylation of tau is generally correlated with the
formation of tau protein aggregates which are major compo-
nents of neuroﬁbrillary tangles, one of themainneuropathological
hallmarks of AD which is also observed in other tauopathies
including PD. Phosphorylated tau alsomore speciﬁcally inﬂuences
FIGURE 3 | Schematic representation of the tau protein and its
phosphorylation sites. Depicted in red are mutations associated with
frontotemporal dementia and parkinsonism linked to chromosome 17
(FTDP-17). Four main classes of phosphatases reported to regulate tau
phosphorylation are given above the schematic. (Tau schematic adapted
from Martin et al., 2011 and Tenreiro et al., 2014). Please refer to Table 3
for an overview of sites regulated by each of the four main tau
phosphatase classes.
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its afﬁnity formicrotubules and high phosphorylation levels of tau
have been reported to negatively inﬂuence cytoskeleton, synap-
tic functions as well as cell viability (Buee et al., 2000). Recently,
some work has appeared showing some differences in the tau
phosphorylation pattern in post-mortem brain of tauopathies,
including PD (Duka et al., 2013). This work revealed notable
differences in phosphorylation patterns between PD and other
tauopathies. For instance, S202, T205, S262, S409 are hyper-
phosphorylated in AD and DLB, but are unchanged in PD, while
others such as T181, S184, S195, S198, S237, S400 are hyper-
phosphorylated in all three, AD, DLB, and PD. It remains to
be conﬁrmed that these varying phosphorylation patterns are
indeed related to the varying pathology observed in these different
diseases.
PHOSPHATASES OF TAU
In light of the importance of tau phosphorylation for its pathology,
several studies have sought to identify phosphatases dephosphory-
lating tau (reviewed in Martin et al., 2013a). These studies reveal
a predominant role for PP2A, which is the most efﬁcient phos-
phatase to dephosphorylate tau in vitro at S202, S262, and S356,
but not S396 (Bennecib et al., 2000; Kuszczyk et al., 2009; Martin
et al., 2009). This ﬁnding has been related to AD where to PP2A
activity is reduced by up to 50% in AD brains (Voronkov et al.,
2011; Martin et al., 2013a), observations pointing towards the
potential of targeting PP2A for therapy in tauopathies, although
this relation has yet to be explored in PD. Besides the major role
for PP2A, other phosphatases have also been found to act on tau
phosphorylation. For instance, PP1 has been reported to act on
tau at a limited number of sites in AD brains (T212, T217, S262,
S396, S422; Rahman et al., 2005). Similarly, PP2B (aka calcineurin)
is able to dephosphorylate tau at S262 and S396 (Rahman et al.,
2006) while PP5 is reported to dephosphorylate tau at sites S198–
S199–S202, T231–S235, S262–S356, S396–S404, and S422 (Gong
et al., 2004). An overview of these four classes of phosphatases
and the precise sites reported to be regulated by each is given in
Table 3.
Thus far, the precise regulatory subunits, which may render
speciﬁcity of these phosphatases to speciﬁc tau phosphosites, have
yet to be elucidated and conﬁrmed. Some evidence points to the
importance of the PP2A regulatory Bα subunit in PP2A mediated
phosphoregulation of tau. Expression of the Bα subunit of PP2A
is decreased in frontal and temporal cortices of AD brain (Sontag
et al., 1999, 2004), although it is not known if Bα subunit expres-
sion is altered in PD brain. In in vitro assays, the Bα subunit is
found to direct the PP2A holoenzyme to microtubules (Xu et al.,
2008; Virshup and Shenolikar, 2009), consistent with a role for the
Bα subunit in the PP2A holoenzyme dephosphorylating tau.
POTENTIAL INTERPLAY BETWEEN PHOSPHORYLATION OF
LRRK2, α-SYN, AND TAU
As LRRK2, α-syn, and tau are all three involved in dominant
Parkinsonism, the hypothesis has been put forward that these
three proteins interact in pathological pathways (Taymans and
Cookson, 2010), most notably with synuclein and tau acting
as toxic proteins and LRRK2 acting as an upstream modulator.
Experimental evidence from animal models has begun to sup-
port the hypothesis of an interaction between these proteins in
PD pathology. For instance, toxicity induced by high α-syn levels
in mouse brain is attenuated in LRRK2 knockout mice, both in
transgenic mice with high α-syn (inducible CaMKII promoter)
expression levels (Lin et al., 2009) as well as after viral delivery
of α-syn (Daher et al., 2014), although this has not been repli-
cated in other transgenic mice using other promoters to drive
LRRK2 and α-syn expression such as the Thy1 promoter (Herzig
et al., 2012) or PrP promoter (Daher et al., 2012) suggesting that
the effect is dependent on expression patterns or levels. Several
reports show that LRRK2 overexpression affects tau expression
or tau phosphorylation (see below), supporting the hypothesis
that LRRK2 modulates tau although whether LRRK2 is required
for tau toxicity has yet to be tested. Interestingly, the injection
of α-syn ﬁbrillar strains into mouse brain is shown to induce
tau aggregation (Guo et al., 2013), suggesting an interconnec-
tion between α-syn and tau pathological mechanisms. Studies of
relationships between LRRK2, α-syn, and tau showing pairwise
interactions between these proteins suggest that 3-way interac-
tion studies, which are currently still lacking, are warranted. More
information on the overall interplay between these three proteins
in PD pathology can be found in recent reviews covering this
topic (Greggio et al., 2011; Tenreiro et al., 2014). With regards
to the topic of the present review, we highlight below the rela-
tionships between LRRK2, α-syn, and tau with regard to their
phosphorylation regulation.
As LRRK2 is a kinase, it has been hypothesized that LRRK2may
phosphorylate α-syn or tau. Direct phosphorylation of α-syn by
LRRK2 in vitro has been tested, however, this led to negative results
[reference (Khan et al., 2005) and JMT, VB unpublished results].
Also, in LRRK2 overexpressing mice, phosphorylation levels of α-
syn at S129 were found to be unchanged (Herzig et al., 2012) or
even reduced compared to controls (Lin et al., 2009), countering
the hypothesis that LRRK2 phosphorylates α-syn. Qing and col-
leagues reported that crude lysates of E. coli expressing LRRK2 as
source of enzyme could phosphorylate α-syn at S129, suggesting
that LRRK2 may regulate α-syn phosphorylation in conjunction
with bacterial proteins (Qing et al., 2009), although this is unlikely
to be representative of a human physiological situation. The direct
phosphorylation of α-syn by LRRK2 can therefore be excluded.
There is, however, evidence that LRRK2 may be involved in
regulating tau phosphorylation. First, tau pathology has been
observed in post-mortem brain of LRRK2 mutation carriers,
including in carriers of the I1371V (Biernacka et al., 2011),
N1437H (Puschmann et al., 2012), R1441C (Zimprich et al.,
2004), Y1699C (Khan et al., 2005), G2019S (Lin et al., 2010),
and I2020T (Ujiie et al., 2012) LRRK2 mutations. Interestingly,
genetic studies suggest that tau variants inﬂuence LRRK2 dis-
ease, more speciﬁcally by inﬂuencing the age of disease onset
(Gan-Or et al., 2012), although another study found that inter-
actions between LRRK2 and tau were at the limit of statistical
signiﬁcance (Biernacka et al., 2011). In cells and in vivo, several
pieces of evidence point to LRRK2 in regulating tau phos-
phorylation. MacLeod et al. (2006) found that overexpressed
LRRK2 G2019S or I2020T in primary neurons colocalized with
phospho-tau punctae in axons. Overexpression of LRRK2 via
www.frontiersin.org November 2014 | Volume 5 | Article 382 | 7
Taymans and Baekelandt Phosphatases of α-syn, LRRK2, and tau
Table 3 | Overview of different classes of phosphatases reported to regulate tau phosphorylation sites, including PP1, PP2A, PP2B, and PP5.
Site PP1 PP2A PP2B PP5
S198 Gong et al. (2004)
S199 Liu et al. (2005) Liu et al. (2005) Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Gong et al. (2004), Liu et al. (2005)
S202 Liu et al. (2005) Liu et al. (2005), Kuszczyk et al.
(2009), Martin et al. (2009)
Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Gong et al. (2004), Liu et al. (2005)
T205 Liu et al. (2005) Liu et al. (2005), Kuszczyk et al.
(2009), Martin et al. (2009)
Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Liu et al. (2005)
T212 Liu et al. (2005),
Rahman et al. (2005)
Liu et al. (2005) Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Liu et al. (2005)
S214 Liu et al. (2005) Liu et al. (2005) Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Liu et al. (2005)
T217 Rahman et al. (2005) Saito et al. (1995), Bennecib et al. (2000),
Rahman et al. (2006)
T231 Saito et al. (1995), Chen et al. (2008) Gong et al. (2004)
S235 Liu et al. (2005) Saito et al. (1995), Liu et al. (2005),
Chen et al. (2008)
Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Gong et al. (2004), Liu et al. (2005)
S262 Liu et al. (2005),
Rahman et al. (2005)
Saito et al. (1995), Liu et al. (2005),
Chen et al. (2008), Martin et al. (2009)
Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Gong et al. (2004), Liu et al. (2005)
S293
S324
S356 Saito et al. (1995), Chen et al. (2008),
Martin et al. (2009)
Gong et al. (2004)
S396 Liu et al. (2005),
Rahman et al. (2005)
Liu et al. (2005) Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Gong et al. (2004), Liu et al. (2005)
S404 Liu et al. (2005) Saito et al. (1995), Liu et al. (2005),
Chen et al. (2008)
Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Gong et al. (2004), Liu et al. (2005)
S409 Liu et al. (2005) Liu et al. (2005) Saito et al. (1995), Bennecib et al. (2000),
Liu et al. (2005), Rahman et al. (2006)
Liu et al. (2005)
S422 Rahman et al. (2005) Saito et al. (1995), Bennecib et al. (2000),
Rahman et al. (2006)
Gong et al. (2004)
References of reports showing activity of phosphatases per phosphorylation site mentioned in the ﬁrst cell of each table row are given in the column of the
corresponding phosphatase class. See text for a list of reviews discussing non-phosphatase tau phosphorylation regulators.
the ThyI promoter left tau and phospho-tau (S202/T205) levels
unchanged in mouse brains (Herzig et al., 2012), although S202
phosphorylation levels were found to be enhanced in brains of
BAC transgenic mice expressing LRRK2 G2019S (Melrose et al.,
2010). InDrosophila, overexpression of LRRK2G2019S is reported
to affect tau dendritic localization and promote tau phosphoryla-
tion at T212 through the recruitment of GSK3β (Lin et al., 2010).
Interestingly, LRRK2 has been shown to phosphorylate tubulin-
associated tau but not free tau (Kawakami et al., 2012). This last
ﬁnding may be related to the observations in cells that LRRK2
can in certain conditions translocate to skein-like cytoplasmic
pools. Although these skein-like cytoplasmic pools have yet to
be fully characterized, at least a portion of these are associated
to microtubules (Kett et al., 2012). This points to a mechanism
whereby LRRK2 may be recruited to microtubules where it may
regulate tau phosphorylation with other kinase or phosphatase
partners.
In relation to our knowledge of phosphatases of LRRK2, α-
syn, and tau and the pathogenic nature of phosphorylations in
these proteins, a strategy to target phosphatases in a way that
will counteract PD-associated phosphorylation can be proposed.
To target LRRK2 disease-related phosphorylations, PP1 would
be targeted in order to modulate phosphorylation at its ANK-
LRR interdomain phosphorylation sites to a ‘healthy’ level. For
instance, pharmacological inhibition of PP1was shown to increase
the S910/S935/S955/S973 phosphorylation to levels comparable
to WT. Also, PP1 inhibition was able to reduce the prevalence
of LRRK2 presence in skein-like structures observed with sev-
eral hypophosphorylated diseasemutants (Lobbestael et al., 2013).
This effect is consistent with a reduction of microtubule associated
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LRRK2 and therefore reduced risk of LRRK2-mediated tau hyper-
phosphorylation, suggesting that PP1 inhibition may be a viable
therapeutic strategy to inhibit LRRK2 mediated pathology. Thus
far, the speciﬁc composition of the PP1 holoenzyme targeting
the ANK-LRR interdomain sites remains to be elucidated prior
to developing LRRK2-speciﬁc phosphoregulation strategies. Also,
the elucidation of phosphatases regulating other sites, such as
S1292, may also reveal other potential phosphatase targets for
potential therapies targeting LRRK2 phosphorylation.
For α-syn, targeting PP2A holo-enzymes is a preferred strategy,
more speciﬁcally through the activation of PP2A to reduce α-syn-
S129 phosphorylation levels. The potential of this approach has
been shown by pharmacologically enhancing PP2A activity (see
above; Lee et al., 2011). The precise PP2A holoenzyme composi-
tion for α-syn-S129 has begun to be elucidated, with a preference
for the B regulatory subunit above B′ andB′′ subunits. Further elu-
cidation of the preferred C (catalytic) andA (scaffolding) subunits
for α-syn-S129 will allow development of phosphatase activation
by targeting the PP2A holoenzyme.
For tau, several phosphatases may be targeted, including PP2A,
PP1, PP2B, or PP5. The predominant role of PP2A suggests that
activation of PP2A may also be a beneﬁcial therapeutic strategy.
One issue is whether separate PP2A holoenzymes are responsible
for dephosphorylation of tau at the separate phosphosites. Specif-
ically for PD, it may be expected that dephosphorylation of tau
at PD hyperphosphorylation sites should be targeted prioritar-
ily, including T181, S184, S195, S198, S237, S400 (Duka et al.,
2013). Further research will be needed to describe the PD-tau
phosphorylations and their regulation.
TARGETING OF PHOSPHATASES
Modulation of phosphorylation levels of disease proteins is an
attractive approach to develop disease modifying therapies. For
instance, much effort has been spent on targeting kinases respon-
sible for pathogenic phosphorylations. Kinases are also attractive
drug targets. Indeed, attrition rates during development of drugs
acting on kinases are lower than for most other classes of drugs
(Walker and Newell, 2009). An important factor to bear in mind
with pharmacological inhibition of kinases is that this will inﬂu-
ence the phosphorylation levels of all of the kinase’s substrates,
both in the disease protein as well as for all of its other substrates.
Therefore, for key phosphorylations, it may be necessary to target
phosphorylations through other means than by targeting kinases.
One possibility is to target phosphatases.
Phosphatases are divided into different classes, including
phosphoprotein phosphatases (PPP), metal-dependent protein
phosphatases and protein tyrosine phosphatases (PTP). Phos-
phatases from the PPP class are responsible for the vast majority
of dephosphorylations of central nervous system proteins. PPPs,
such as PP1 and PP2A class phosphatases, have the characteristic
of functioning as a holoenzyme composed of two or more sub-
units, including a catalytic subunit as well as regulatory subunits.
Interestingly, there are few catalytic subunits in the PPP family
and the regulatory subunits have therefore generally been thought
to confer substrate speciﬁcity to the holoenzyme. Emerging struc-
tural evidence is supporting this view, namely that phosphatase
holoenzymes of the PPP family associate in a structured way
and that this structure determines substrate speciﬁcity of the
dephosphorylation. Some examples are the interaction between
PP1 and spinophilin, a complex found in neurons (Ragusa et al.,
2010), and the PP1γ–MYPT (myosin phosphatase; PPP1R12A)
complex that acts as a myosin phosphatase in muscle (Terrak
et al., 2014; Yamashiro et al., 2008). Based on this knowledge, it
has been proposed that by targeting the holoenzyme structure,
for instance by molecules which disrupt substrate-phosphatase
holoenzyme complex, one can speciﬁcally modulate phosphory-
lation levels of proteins (McConnell andWadzinski, 2009; Tsaytler
and Bertolotti, 2013; see conceptual schematic in Figure 4).
Based on the knowledge of the phosphatases responsible for
dephosphorylation of speciﬁc phosphosites of proteins, such as
emerging knowledge of the composition of phosphatase holoen-
zymes dephosphorylating speciﬁc sites in α-syn, LRRK2, and
tau, the speciﬁc modulation of phosphorylation levels of single
phosphosites is theoretically possible. Further work, including
further identiﬁcation and characterization of speciﬁc phosphatase
holoenzyme compositions for α-syn, LRRK2, and tau and devel-
opment of modulators of phosphatase holoenzyme complexes
with their speciﬁc substrates, is required to test the efﬁcacy of
this approach.
CONCLUSION
The three main proteins linked to Parkinsonism, α-syn, tau, and
LRRK2 all display phosphorylationswhich aremodiﬁed in disease.
The phosphorylation changes are the result of a balance between
activity of kinases and phosphatases. Emerging evidence points to
phosphatases regulating different pathological phosphorylations
in these three proteins, primarily PP1 for LRRK2 and PP2A for
α-syn and tau. It appears now feasible to target phosphatases
of α-syn, tau, and LRRK2 in order to alleviate pathology medi-
ated by pathological phosphorylation of these disease proteins.
In order for this approach to reach its full potential, additional
research will be required further linking individual or clustered
phosphorylation events in these three proteins to disease. Also,
FIGURE 4 | Regulation of protein phosphorylation via modulators of
phosphatase holoenzymes. Several phosphatase classes, such as PP1
and PP2A class phosphatases depicted here function as multiprotein
holoenzymes including a catalytic subunit and regulatory subunits.
Phosphatase activity can be modulated by protein-protein interaction
modulators (depicted here as red studded bars) which can either disrupt
the holoenzyme complex itself or disrupt binding of the holoenzyme to its
substrate.
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reﬁned knowledge of the precise holoenzyme compositions for
each pathological phosphorylation is necessary to develop highly
speciﬁc phosphatase holoenzyme modulators.
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